-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Downgrades Dyne Therapeutics to Perform, Lowers Price Target to $15

Benzinga·10/28/2026 12:33:36
语音播报
Oppenheimer analyst Kostas Biliouris downgrades Dyne Therapeutics (NASDAQ:DYN) from Outperform to Perform and lowers the price target from $40 to $15.